<?xml version='1.0' encoding='utf-8'?>
<document id="25184238"><sentence text="Multicenter study of trimethoprim/sulfamethoxazole-related hepatotoxicity: incidence and associated factors among HIV-infected patients treated for Pneumocystis jirovecii pneumonia."><entity charOffset="21-33" id="DDI-PubMed.25184238.s1.e0" text="trimethoprim" /><entity charOffset="34-50" id="DDI-PubMed.25184238.s1.e1" text="sulfamethoxazole" /><pair ddi="false" e1="DDI-PubMed.25184238.s1.e0" e2="DDI-PubMed.25184238.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25184238.s1.e0" e2="DDI-PubMed.25184238.s1.e1" /></sentence><sentence text="The incidence of hepatotoxicity related to trimethoprim/sulfamethoxazole (TMP/SMX) administered at a therapeutic dose may vary among study populations of different ethnicities and hepatotoxic metabolites of TMP/SMX may be decreased by drug-drug interaction with fluconazole"><entity charOffset="43-55" id="DDI-PubMed.25184238.s2.e0" text="trimethoprim" /><entity charOffset="56-72" id="DDI-PubMed.25184238.s2.e1" text="sulfamethoxazole" /><entity charOffset="74-77" id="DDI-PubMed.25184238.s2.e2" text="TMP" /><entity charOffset="207-210" id="DDI-PubMed.25184238.s2.e3" text="TMP" /><entity charOffset="262-273" id="DDI-PubMed.25184238.s2.e4" text="fluconazole" /><pair ddi="false" e1="DDI-PubMed.25184238.s2.e0" e2="DDI-PubMed.25184238.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25184238.s2.e0" e2="DDI-PubMed.25184238.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25184238.s2.e0" e2="DDI-PubMed.25184238.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25184238.s2.e0" e2="DDI-PubMed.25184238.s2.e3" /><pair ddi="false" e1="DDI-PubMed.25184238.s2.e0" e2="DDI-PubMed.25184238.s2.e4" /><pair ddi="false" e1="DDI-PubMed.25184238.s2.e1" e2="DDI-PubMed.25184238.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25184238.s2.e1" e2="DDI-PubMed.25184238.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25184238.s2.e1" e2="DDI-PubMed.25184238.s2.e3" /><pair ddi="false" e1="DDI-PubMed.25184238.s2.e1" e2="DDI-PubMed.25184238.s2.e4" /><pair ddi="false" e1="DDI-PubMed.25184238.s2.e2" e2="DDI-PubMed.25184238.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25184238.s2.e2" e2="DDI-PubMed.25184238.s2.e3" /><pair ddi="false" e1="DDI-PubMed.25184238.s2.e2" e2="DDI-PubMed.25184238.s2.e4" /><pair ddi="false" e1="DDI-PubMed.25184238.s2.e3" e2="DDI-PubMed.25184238.s2.e3" /><pair ddi="false" e1="DDI-PubMed.25184238.s2.e3" e2="DDI-PubMed.25184238.s2.e4" /></sentence><sentence text=" We aimed to investigate the incidence of hepatotoxicity and the role of concomitant use of fluconazole in HIV-infected patients receiving TMP/SMX for Pneumocystis jirovecii pneumonia"><entity charOffset="92-103" id="DDI-PubMed.25184238.s3.e0" text="fluconazole" /><entity charOffset="139-142" id="DDI-PubMed.25184238.s3.e1" text="TMP" /><pair ddi="false" e1="DDI-PubMed.25184238.s3.e0" e2="DDI-PubMed.25184238.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25184238.s3.e0" e2="DDI-PubMed.25184238.s3.e1" /></sentence><sentence text=" We reviewed medical records to collect clinical characteristics and laboratory data of HIV-infected patients who received TMP/SMX for treatment of P"><entity charOffset="123-126" id="DDI-PubMed.25184238.s4.e0" text="TMP" /></sentence><sentence text=" jirovecii pneumonia at 6 hospitals around Taiwan between September 2009 and February 2013" /><sentence text=" Hepatotoxicity was defined as 2-fold or greater increase of aminotransferase or total bilirubin level from baselines"><entity charOffset="87-96" id="DDI-PubMed.25184238.s6.e0" text="bilirubin" /></sentence><sentence text=" Roussel UCLAF Causality Assessment Method (RUCAM) was used to analyze the causality of drug-induced liver injuries" /><sentence text=" NAT1 and NAT2 acetylator types were determined with the use of polymerase-chain-reaction (PCR) restriction fragment length polymorphism to differentiate common single-nucleotide polymorphisms (SNPs) predictive of the acetylator phenotypes in a subgroup of patients" /><sentence text=" During the study period, 286 courses of TMP/SMX treatment administered to 284 patients were analyzed"><entity charOffset="41-44" id="DDI-PubMed.25184238.s9.e0" text="TMP" /></sentence><sentence text=" One hundred and fifty-two patients (53" /><sentence text="1%) developed hepatotoxicity, and TMP/SMX was considered causative in 47 (16"><entity charOffset="34-36" id="DDI-PubMed.25184238.s11.e0" text="TMP" /></sentence><sentence text="4%) who had a RUCAM score of 6 or greater" /><sentence text=" In multivariate analysis, concomitant use of fluconazole for candidiasis was the only factor associated with reduced risk for hepatotoxicity (adjusted odds ratio, 0"><entity charOffset="46-57" id="DDI-PubMed.25184238.s13.e0" text="fluconazole" /></sentence><sentence text="372; 95% confidence interval, 0" /><sentence text="145-0" /><sentence text="957), while serostatus of hepatitis B or C virus, NAT1 and NAT2 acetylator types, or receipt of combination antiretroviral therapy was not" /><sentence text=" The incidence of hepatotoxicity decreased with an increasing daily dose of fluconazole up to 4"><entity charOffset="76-87" id="DDI-PubMed.25184238.s17.e0" text="fluconazole" /></sentence><sentence text="0 mg/kg" /><sentence text=" We conclude that the incidence of TMP/SMX-related hepatotoxicity was 16"><entity charOffset="35-38" id="DDI-PubMed.25184238.s19.e0" text="TMP" /></sentence><sentence text="4% in HIV-infected Taiwanese patients who received TMP/SMX for pneumocystosis"><entity charOffset="51-54" id="DDI-PubMed.25184238.s20.e0" text="TMP" /></sentence><sentence text=" Concomitant use of fluconazole was associated with decreased risk for TMP/SMX-related hepatotoxicity"><entity charOffset="20-31" id="DDI-PubMed.25184238.s21.e0" text="fluconazole" /><entity charOffset="71-81" id="DDI-PubMed.25184238.s21.e1" text="TMP" /><pair ddi="false" e1="DDI-PubMed.25184238.s21.e0" e2="DDI-PubMed.25184238.s21.e0" /><pair ddi="false" e1="DDI-PubMed.25184238.s21.e0" e2="DDI-PubMed.25184238.s21.e1" /></sentence><sentence text=" " /></document>